Christina is the associate editorial director of The American Journal of Managed Care® (AJMC®) and Population Health, Equity & Outcomes, and joined AJMC in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.
She has a BS in public health from Rutgers University. You can connect with Christina on LinkedIn.
Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
A provision in the Inflation Reduction Act will implement a $2000 out-of-pocket cap on Medicare beneficiaries’ prescription drug spending, which could save money for more than 1 million enrollees when it takes effect next year.
Four years after the publication of data showing that the Camden Coalition’s “hotspotting” care management program did not reduce hospital readmissions, the investigators have published new work delving into the mechanisms behind the null findings.
In 2023, the most-read articles published in The American Journal of Accountable Care® (AJAC) highlighted innovative care models, lessons learned from health system partnerships, and much more.
The editors in chief of The American Journal of Managed Care® discuss the managed care developments of 2023 and anticipate trends on the horizon.
In 2023, the most-read articles published in the peer-reviewed The American Journal of Managed Care® (AJMC®) explored predictive models, opioid prescribing, and much more.
A new report from AHIP shows that Medicare Advantage outperformed traditional Medicare on several clinical quality measures, including preventive screenings. However, debate continues over these plans’ cost efficiency and impact on the financial sustainability of rural hospitals.
Health care providers and policy experts gathered in New Orleans, Louisiana, to discuss the complex interplay between food insecurity and obesity as well as the expanding toolbox of options to support patients in achieving a healthy weight.
Clinicians and leaders from Duke University convened in Durham, North Carolina, to discuss unmet needs in the care of patients with diabetes and opportunities to close those gaps through coordination, education, support, and technology.
After recent policy changes removing most medical debts from credit reports, Americans are seeing their credit scores increase, but experts warn of the need to monitor billing and collection practices for unintended consequences.
Amal Trivedi, MD, MPH, professor at Brown University, discusses the qualities that led him to nominate David J. Meyers, PhD, to receive the Seema S. Sonnad Emerging Leader in Managed Care Research Award. The American Journal of Managed Care® presented the award to Dr Meyers at the 2023 Patient-Centered Oncology Care® meeting.
Half of the surveyed adults reported difficulty affording their health care, and a large proportion said they delayed or avoided care or medication because they couldn’t afford it, often leading to their health problems worsening.
A 5-year randomized trial showed that the Million Hearts Model, which paid health care organizations to monitor and reduce cardiovascular disease (CVD) risk, was effective in reducing first-time heart attacks and strokes without associated increases in Medicare spending.
Vast claims databases can yield valuable information about the unmet medical needs of patients with chronic obstructive pulmonary disease (COPD) and severe asthma, and those insights point to areas that can be improved by engaging and educating clinicians.
Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single inhaler that delivers triple therapy.
With methamphetamines continuing to inflict damage on the Western United States, panelists at the CHEST Annual Meeting 2023 shared sobering statistics and important considerations in treating patients with pulmonary hypertension associated with use of this destructive drug.
Amid the impacts of climate change, industrial emissions, and environmental disasters, pulmonologists and other clinicians will need to deliver actionable advice on how to reduce the risks to lung health posed by air pollution, according to panelists at the CHEST Annual Meeting 2023.
Increasing lung cancer screening uptake without tailoring outreach and follow-up for underserved populations risks magnifying the existing racial and ethnic disparities in screening, so thoughtful approaches are needed to close the gaps, according to speakers at the CHEST Annual Meeting 2023.
New research explores the risk factors for lung disease in firefighters who were exposed to particulate matter when responding to the attacks on the World Trade Center (WTC) on September 11, 2001, as well as interventions that may mediate inflammatory responses.
As evidenced by a debate at the CHEST Annual Meeting 2023, the pulmonology community disagrees on whether the overlap of asthma and chronic obstructive pulmonary disease (COPD) is a distinct entity and how best to treat it.
The CHEST Annual Meeting 2023 will take place in Honolulu, Hawai‘i, from October 8-11, as pulmonologists and researchers from a multitude of specialties convene to discuss pressing topics, including the role of air pollution in lung health.
The 10 drugs, spanning disease states from diabetes to heart failure to rheumatoid arthritis, cost Medicare enrollees a total of $3.4 billion in out-of-pocket costs in 2022. As required by the Inflation Reduction Act (IRA), negotiations between Part D and pharmaceutical companies will take place this year and next, with the negotiated prices taking effect in 2026.
Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.
Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.
The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.
Newly presented data reveal disparities between Black and White patients in both the characteristics of and the decision-making around treatment for chronic lymphocytic leukemia (CLL) and multiple myeloma, respectively.
With the number of treatment options in hematology and oncology rapidly expanding, so too are the strategies for determining and ensuring cost-effectiveness, according to session speakers at the European Hematology Association (EHA) 2023 Congress.
The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes.
Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.
